Vascular Access News

Xeltis announced the clinical trial of the restorative hemodialysis access graft, aXess, showed promising early puncturing, patency and safety data, according to a press release.

Arrow International issued a recall of its percutaneous thrombolytic device due to risk for tip damage during use and subsequent detachment from the basket.

Xeltis, a Swiss-Dutch medical device company, reported that it implanted patients with kidney failure who required dialysis with aXess, the first restorative synthetic hemodialysis access graft.

A meta-analysis revealed no significant difference in primary study outcomes using Ellipsys or WavelinQ to create arteriovenous fistulas in patients requiring access for dialysis.

Skin markings identifying the direction and angle of buttonhole cannulations can make the procedure less painful and anxiety-inducing for patients, according to data published in Kidney Medicine.

The FDA granted breakthrough device designation to First Assist Devices LLC for its First Assist Model FA-1 device, according to a press release.

Patients with a higher degree of frailty are more likely to experience a longer wait time for fistula and graft functional use after dialysis initiation, according to data published in the American Journal of Kidney Diseases.

The Dialysis Vascular Access Coalition and other national advocacy groups are racing against the clock to reverse proposed payment cuts – set to take effect Jan. 1 – on vascular access procedures done by interventionalists and surgeons.

Fresenius Medical Care AG has invested an additional $25 million in clinical-stage biotechnology platform company Humacyte Inc., following an initial investment of $150 million made in 2018.

The type of arteriovenous access placement, graft or fistula, used first in older patients receiving hemodialysis did not impact their risk for death, sepsis or hospitalization.